Zaki, M., Hadid, K., Khudhur, Z., Al-Hammodi, B., Abed, M., Alassaf, F., Saeed, N. (2025). Comparative Study of Tamsulosin and Alfuzosin on Irritative Symptoms in Benign Prostatic Hyperplasia: Efficacy and Tolerability. , 22(4), 180-185. doi: 10.33899/iraqij.p.2025.163110.1164
Muthanna K. Zaki; Khalil A. Hadid; Zaid S. Khudhur; Bashar M. Al-Hammodi; Mohammed N. Abed; Fawaz A. Alassaf; Nooman Hadi Saeed. "Comparative Study of Tamsulosin and Alfuzosin on Irritative Symptoms in Benign Prostatic Hyperplasia: Efficacy and Tolerability". , 22, 4, 2025, 180-185. doi: 10.33899/iraqij.p.2025.163110.1164
Zaki, M., Hadid, K., Khudhur, Z., Al-Hammodi, B., Abed, M., Alassaf, F., Saeed, N. (2025). 'Comparative Study of Tamsulosin and Alfuzosin on Irritative Symptoms in Benign Prostatic Hyperplasia: Efficacy and Tolerability', , 22(4), pp. 180-185. doi: 10.33899/iraqij.p.2025.163110.1164
Zaki, M., Hadid, K., Khudhur, Z., Al-Hammodi, B., Abed, M., Alassaf, F., Saeed, N. Comparative Study of Tamsulosin and Alfuzosin on Irritative Symptoms in Benign Prostatic Hyperplasia: Efficacy and Tolerability. , 2025; 22(4): 180-185. doi: 10.33899/iraqij.p.2025.163110.1164

Comparative Study of Tamsulosin and Alfuzosin on Irritative Symptoms in Benign Prostatic Hyperplasia: Efficacy and Tolerability

Iraqi Journal of Pharmacy
Article 2, Volume 22, Issue 4, December 2025, Pages 180-185    PDF (517.68 K)
Document Type: Research Paper
DOI: 10.33899/iraqij.p.2025.163110.1164
Authors
Muthanna K. Zaki1; Khalil A. Hadid* 1; Zaid S. Khudhur2; Bashar M. Al-Hammodi3; Mohammed N. Abed4; Fawaz A. Alassaf1; Nooman Hadi Saeed2
1Department of Pharmacology and Toxicology, College of Pharmacy, University of Mosul, Mosul, Iraq
2Department of Surgery, College of Medicine, University of Mosul, Mosul, Iraq
3Al-Jamhoori Teaching Hospital, Mosul Health Directorate, Ministry of Health/Environment, Mosul, Iraq
4Department of Clinical Laboratory Sciences, College of Pharmacy, University of Mosul, Mosul, Iraq
Abstract
Background: : Benign prostatic hyperplasia (BPH) is a common condition in aging men, often presenting with lower urinary tract symptoms, such as frequency, urgency, and nocturia. Tamsulosin and Alfuzosin, α1-adrenergic receptor antagonists, are among the primary pharmacological treatments. The current prospective study aimed to assess the safety and effectiveness of tamsulosin and alfuzosin in patients with BPH without dosage titration over a period of 4 weeks. Methods: A total of 52 patients were involved in this study, presenting with irritative symptoms of BPH and aged 45 years and above. Participants were then divided into two groups: the Tamsulosin group (26 participants), who received tamsulosin 0.4 mg, and the alfuzosin group (26 participants), who received alfuzosin 10 mg. The irritative score of the International Prostate Symptom Score (IPSS) questionnaire was used to assess the participants, in addition to the post-void residual volume (PVRV) by ultrasonography. Results: Baseline characteristics, including PVRV, were similar between groups. Tamsulosin and alfuzosin reduce BPH irritative symptoms similarly. Both significantly reduce frequency, urgency, and nocturia (p < 0.0001). However, the study compared change scores between groups; tamsulosin showed a greater mean reduction in PVRV than alfuzosin on between-group testing. Side effects were minimal; 4% of patients in the alfuzosin group experienced hypotension, and 4% reported sexual dysfunction, while no side effects were observed in the tamsulosin group. Conclusion: Treatment with tamsulosin or alfuzosin demonstrates significant improvement in the irritative symptoms of BPH, with both drugs showing comparable efficacy, while a numerically greater reduction in PVRV is observed with tamsulosin. No significant side effects were reported that affected the tolerability of either medication.  
Keywords
Alfuzosin; BPH; IPSS; Irritative symptoms; Tamsulosin
References
  1. Jiwrajka M, Yaxley W, Perera M, Roberts M, Dunglison N, Yaxley J, et al. Review and update of benign prostatic hyperplasia in general practice. Australian Journal of General Practice 2018;47(7):471–5.
  2. Unnikrishnan R, Almassi N, Fareed K. Benign prostatic hyperplasia: Evaluation and medical management in primary care. Cleveland Clinic Journal of Medicine 2017;84(1):53–64.
  3. Gravbrot N, Odei B, Johnson SB, Tward JD. International Prostate Symptom Score Outcomes of Five Different Treatment Paradigms for Localized Prostate Cancer: A Single-Institution Experience. International Journal of Radiation Oncology, Biology, and Physics 2024;120(2):e533.
  4. Liu C, Wang C, Huang S, Chou Y, Wu W, Huang C. Relationships Between American Urological Association Symptom Index, Prostate Volume, and Disease-Specific Quality of Life Question in Patients with Benign Prostatic Hyperplasia. The Kaohsiung Journal of Medical Sciences 2004;20(6):273–8.
  5. Blanker MH, Alma HJ, Devji TS, Roelofs M, Steffens MG, van der Worp H. Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care. BMJ Open 2019;9(12):e032795.
  6. Akinaga J, García-Sáinz JA, S. Pupo A. Updates in the function and regulation of α 1-adrenoceptors. British Journal of Pharmacology 2019;176(14):2343–57.
  7. Seo YM, Kim HJ. Effect of Alpha-Blockers on Patients with Benign Prostatic Hyperplasia with Inflammatory Cells in the Prostatic Fluid. Urogenital Tract Infection 2018;13(2):40–4.
  8. Visingardi J, Walia J, Jawiche J, Feustel PJ, De EJB. Surprising clinical differences among alpha blockers demonstrated in post-marketing event rates. Continence 2024;12:101696.
  9. Osman T, Elawady H, Fawaz K, Shabayek M, Essam MD, Osman D, et al. Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement. International Urology and Nephrology 2024;56(6):1811–6.
  •  
  1. Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review. Systems Biology in Reproductive Medicine 2009;55(4):129–36.
  2. Griwan MS, Singh SK, Indora J. Comparison of Alfuzosin and Tamsulosin Once Daily for Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Randomized, Prospective Study. UroToday International Journal 2010;3(3).
  3. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Reviews in urology 2007;9(4):181–90.
  4. Mari A, Antonelli A, Cindolo L, Fusco F, Minervini A, De Nunzio C. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. Therapeutic advances in urology 2021;13:1756287221993283.
  5. Franceschini N, Chasman DI, Cooper-DeHoff RM, Arnett DK. Genetics, Ancestry, and Hypertension: Implications for Targeted Antihypertensive Therapies. Current Hypertension Reports 2014;16(8):461.
  6. Rehman A, Ullah S, Haider S, Ahmed Y, Sajjad A. International Prostate Symptom Score (IPSS) Correlation With Sonographic Prostate Size. Biological and Clinical Sciences Research Journal 2024;2024(1):827.
  7. Yu ZJ, Yan HL, Xu FH, Chao HC, Deng LH, Xu XD, et al. Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. Frontiers in Pharmacology 2020;11.
  8. Ye Z, Wang J, Xiao Y, Luo J, Xu L, Chen Z. Global burden of benign prostatic hyperplasia in males aged 60–90 years from 1990 to 2019: results from the global burden of disease study 2019. BMC Urology 2024;24(1):193.
  9. Mari A, Antonelli A, Cindolo L, Fusco F, Minervini A, De Nunzio C. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. Therapeutic Advances in Urology 2021;13:1–15.
  10. Buzelin Jm, Fonteyne E, Kontturi M, Witjes WPJ. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). British Journal of Urology 1997;80(4):597–605.
  11. Agrawal MS, Yadav A, Yadav H, Singh AK, Lavania P, Jaiman R. A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian journal of urology 2009;25(4):474–8.
  12. Dash A, Kumar T, Pandey BL. Efficacy and Safety of Tamsulosin-MR Versus Alfuzosin-SR for Treatment of Symptomatic Benign Prostatic Hyperplasia: A Randomized, Prospective Study. UroToday International Journal 2010;3(3). 
Statistics
Article View: 332
PDF Download: 170


Journal Management System. Powered by iJournalPro.com